



VGX Pharmaceuticals announces a license agreement with VGX International to use CELLECTRA™ electroporation device to develop new DNA-based vaccines and therapies

Blue Bell, PA – April 16, 2008 –

VGX Pharmaceuticals announced today that the Company has granted VGX International, its affiliate based in Seoul, Korea, an exclusive license to use the Company's patented CELLECTRA™ adaptive constant current electroporation device to develop novel DNA vaccines and therapeutics in Korea.

Over the years, VGX Pharmaceuticals has established itself as a leading developer and manufacturer of DNA plasmid-based vaccines and therapies. The Company has built extensive, vertically-integrated capabilities including proprietary SynCon™ DNA-based product candidates, the CELLECTRA™ delivery device, and efficient cGMP manufacturing facilities for its own product supplies and for contract manufacturing.

Earlier this year, VGX Pharmaceuticals submitted a Device Master File (MAF) to the U.S. Food and Drug Administration (FDA) for the CELLECTRA™ device. Numerous preclinical efficacy studies have shown that delivery of DNA-based product candidates with the CELLECTRA™ device improves DNA uptake and its subsequent expression in the target tissue, and results in enhanced immune responses in animals. The MAF filing, which includes technical, manufacturing, and clinical and non-clinical information about a medical device, facilitates FDA review of the CELLECTRA™ device whenever Investigational New Drug (IND) applications for DNA-based product candidates that reference the device's use are filed. VGX Pharmaceuticals recently completed a pain and tolerability clinical trial for its electroporator in healthy volunteers, without the presence of a DNA vaccine, demonstrating that electroporation with the CELLECTRA™ device is well tolerated.

VGX Pharmaceuticals plans to initiate three Phase I trials using three of its novel DNA-based vaccines and therapies delivered by the CELLECTRA™ device. VGX Pharmaceuticals has already filed an IND for VGX-3200, a therapeutic based on human growth hormone releasing hormone (GHRH) for cancer-related cachexia (wasting or heavy weight loss). The Company also plans to file two additional INDs for its SynCon™ DNA vaccine candidates during the second quarter of 2008: VGX-3100, a therapeutic vaccine for the treatment for cervical cancer and VGX-3400, a pandemic avian flu vaccine.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently,

no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, PENNVAX™-B for HIV infection, which is in 2 separate Phase I clinical trials, and VGX-1027 for inflammatory diseases, which is in Phase I clinical trials. In addition, The Company has filed an IND for VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia. VGX has established a vertically-integrated DNA Vaccines and Therapies Platform with extensive capabilities including SynCon™ DNA-based product candidates, the patented CELLECTRA™ delivery device, and efficient cGMP plasmid manufacturing facilities. The cGMP facilities are used for VGX's own product supplies and for contract manufacturing. Vertical control over key aspects of product development has enabled the Company to consistently develop multiple product candidates, from bench-to-IND filing, within 1 year. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

About VGX International

VGX International, a publicly-traded global biopharmaceutical company listed on Korean Stock Exchange. VGX International is a member of the KOSPI 200 index and is headquartered in Seoul, Korea. The Company is dedicated to developing revolutionary new drug candidates for the treatment of cancer and inflammatory diseases, providing the most advanced cGMP solutions for better facilities, and supplying high-end biopharmaceutical products to global clients. The Company's clinical development programs include VGX-1027 for type 1 diabetes and VGX-100 for gastric cancer, which are both currently in pre-clinical stages. The Company provides cGMP manufacturing solutions to other pharmaceutical companies in Asia for new construction of GMP facilities and its related fields. The Company also provides contract manufacturing services dedicated to supplying biopharmaceutical products to global institutions and companies working on DNA therapies. More information about VGX International can be found at www.vgxi.com.

Company Contact:

Kevin W. Rassas
Senior Vice-President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com